Eli Lilly and Company (United States) holds 0 active US FDA Type II Drug Master Files and 40 inactive, has DMF or CEP filings on record for 14 active ingredients and is linked to 6 FDA-registered manufacturing sites. 15 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Eli Lilly and Company: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/eli-lilly-and-company

Overview

Eli Lilly and Company is a global pharmaceutical company known for its innovative contributions to the field of medicine. The company develops, manufactures, and markets pharmaceutical products across a wide range of therapeutic areas. It is committed to advancing medical research and improving patient outcomes.

Core services & business areas

Pharmaceutical ResearchDrug DevelopmentMarketingSalesPharmaceutical ManufacturingRegulatory AffairsSales and MarketingClinical Trials Management

Therapeutic areas

Active ingredients with DMF or CEP filings

Substances for which Eli Lilly and Company holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.

API / Drug Master Files

Eli Lilly and Company holds 0 active (40 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.

  • MDX-068 (HUMANIZED ANTI-B-AMYLOID MONOCLONAL ANTIBODY)Inactive2004-03-15
  • DIPEPTIDYLAMINOPEPTIDASE (DDAP)Inactive2001-06-05
  • CAPREOMYCIN SULFATE, STERILE BULK (CAPASAT)Inactive2001-02-27
  • RECOMBINANT PORCINE CARBOXYPEPTIDASE B (RCPB)Inactive2000-09-18
  • RECOMBINANT BOVINE TRYPSIN (RTRYPSIN)Inactive2000-09-18
  • DIPEPTIDYLAMINOPEPTIDASE (DDAP)Inactive1998-12-08
  • CEFACLORInactive1998-09-01
  • CEFACLORInactive1998-09-01
  • ERYTHROMYCINInactive1998-09-01
  • PENICILLIN G PROCAINEInactive1998-09-01
  • VANCOMYCIN HYDROCHLORIDEInactive1998-09-01
  • CEFAMANDOLE SODIUMInactive1998-09-01
  • CEFAMANDOLE NAFATEInactive1998-09-01
  • ERYTHROMYCIN ESTOLATEInactive1998-09-01
  • CEFUROXIME SODIUMInactive1998-09-01
  • CEFAMANDOLE NAFATEInactive1998-09-01
  • CYCLOSERINEInactive1998-09-01
  • CEPHALEXIN HYDROCHLORIDE,BULKInactive1985-11-12
  • BULK PRODUCTION OF NIZATIDINEInactive1985-09-23
  • BULK PRODUCTION OF NIZATIDINEInactive1985-09-23
  • ACETOHEXAMIDE BULK FORMInactive1984-06-20
  • ACETOHEXAMIDE BULK FORMInactive1984-06-20
  • CINOXACIN, BULK FORMInactive1983-11-15
  • FENOPROFEN CALCIUM, BULK FORMInactive1983-09-16
  • AMPOULES SODIUM THIOSULFATEInactive1980-09-30
  • VIALS DANTRIUM (R)Inactive1979-09-25
  • ACETAMINOPHEN CAPSULESInactive1979-08-22
  • ROTOWEIGH (TM) CAPSULE WEIGHING MACHINE AT USED IN THE INDIANAPOLIS PLInactive1979-03-14
  • ZINC INSULIN CRYSTALS--ARGENTINA DMF-2912Inactive1976-12-22
  • NITROGLYCERIN AMPOULESInactive1972-05-01
  • ASPIRIN CAPSULES 325MGInactive1971-08-02
  • MANUF AND CONTROL INFOR. FOR METHADONE HYDROCHLORIDE DISPERSIBLE TBLSInactive1970-05-27
  • AMPOULES SODIUM THIOCYANATE, INJECTION COMPOUND #23206Inactive1965-12-27
  • TYLOSINInactive1960-06-16
  • IMIDAZOLIUM BROMIDE DERIVATIVEInactive1960-05-16
  • VORTEL TABLETSInactive1959-11-16
  • MYRISTYL - 3 - HYDROXYBUTYLAMINE HCL - COMPOUND 06537Inactive1959-04-20
  • 1 - CYCLOPPENTYL - 2 - AMINO PROPANEInactive1958-08-29
  • CHLORDIETHYLNOL (DIETHYL CHLORO ETHYNYL CARBINOL)Inactive1957-04-08
  • TOPICAL ANESTHETIC COMPOUND C-10Inactive1955-12-22

Registered manufacturing sites (6)

Physical sites registered with the US FDA and resolved to Eli Lilly and Company, with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

15 FDA enforcement records linked to this company.

  • warning_letter2025-09-09

    FDA Warning Letter (drug product)

  • recall — Class II2024-04-24

    CGMP Deviations

  • 4832023-09-15

    Failure to comply with REMS Elements to Assure Safe Use (ETASU) D

  • 4832023-09-15

    Failure to comply with REMS Elements to Assure Safe Use (ETASU) C

  • 4832023-09-15

    Failure to comply with REMS Elements to Assure Safe Use (ETASU) A

  • 4832023-09-15

    Failure to comply with REMS Elements to Assure Safe Use (ETASU) F

  • 4832023-09-15

    Failure to comply with REMS Elements to Assure Safe Use (ETASU) B

  • recall — Class I2021-10-20

    SUBPOTENT DRUG: Vial contained a liquid substance, instead of the expected powder substance. There was also a lack of full drug effect upon administration.

  • recall — Class II2021-09-01

    Labeling: Label error on declared strength - autoinjector devices labeled as 0.75 mg / 0.5 mL actually contain 1.5 mg / 0.5 mL of product.

  • recall — Class II2021-08-18

    cGMP deviations: Atypical appearance, decrease in size and change in color of the lyophilized cake of drug product.

  • recall — Class III2018-11-21

    Labeling: Missing label; potential for missing primary container label on the vial.

  • 4832018-04-23

    Late submission of quarterly safety reports

  • 4832010-09-03

    Late submission of 15-day report

  • 4832010-07-28

    In-process materials specifications

  • 4832010-07-28

    Procedures not in writing, fully followed

For suppliers

Is this Eli Lilly and Company?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.